Summary

Drug Of Abuse Testing Services Market Growth & Trends

The global drug of abuse testing services market size is expected to reach USD 5.46 billion by 2030, registering a CAGR of 4.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of a developed laboratory network and the prevalence of addiction are key drivers for market growth. Furthermore, the increasing trend of different drug use in the community and the importance of testing for the detection of illicit drugs and alcohol is expected to drive the demand. Thereby, continued test offering across the globe has fueled the growth.

Additionally, rising psychiatric disorders patients and hospitalizations due to the consumption of the drugs have boosted the demand. For instance, January 2023, National Survey on Drug Use and Health Results Detailing Mental Illness & Substance Use Levels (2021) was announced by SAMHSA. The survey mentioned that 16.5% of the aged 12 or older population (or 46.3 million) people had a substance use disorder wherein 29.5 million people were classified to have alcohol use disorder & 24 million people had drug use disorder.

In addition, the growing awareness among the population and the unmet need for treatment of addiction and illicit medication use among youth and adults is projected to boost the demand for the drug of abuse testing services industry. For instance, in August 2020, Averhealth announced the acquisition of the drug testing services of the Treatment Assessment Screening Center in Arizona. Therefore, increasing the focus of players to minimize the burden of addiction in emerging countries propels the market revenue. This factor has led companies to develop innovative and effective services for abuse cases.

Likewise, the COVID-19 pandemic has moderately impacted the market. During the pandemic, a constant demand for detection services was attributable to the increased addiction to Cannabis/Marijuana and opioids among the youth and adult population. According to United Nations Office on Drugs and Crime (UNODC), in 2020, around 275 million people used drugs worldwide, while according to the 2021 World Drug Report, over 36 million population suffered from drug use disorders. This factor has led to rising requirements for services post-pandemic.

Furthermore, the key participants are engaged in strategies such as agreements, mergers & acquisitions, partnerships, and launches, among others, to expand their global footprints and product portfolio. For instance, in December 2022, Urine Drugs of Abuse testing services was launched by Omega Laboratories in Canada. Adding to that from January 2023, the laboratory will offer urine testing to complement its molecular testing. The expansion of toxicology services will offer consumers an alternative to limited options available in Canada.

Drug Of Abuse Testing Services Market Report Highlights

• The cannabis/marijuana segment captured the largest revenue share at 57.3% in 2024. Cannabis remains one of the most commonly consumed illicit substances globally.

• The cannabis/marijuana segment is also likely to grow at a fastest CAGR of 5.5% over the forecast period.

• North America drug of abuse testing services market dominated and accounted for a 51.1% share in 2024. The demand for drug testing is increasing due to factors like rising addiction rates, greater drug use in workplaces, and a higher incidence of accidents, along with established healthcare infrastructure.

• Key players operating in the drug of abuse testing services constantly focus on product launches and geographical expansion to maintain their presence

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Regional scope
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in Middle East & Africa
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Drug Of Abuse Testing Services Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High prevalence of substance abuse & growing demand for its treatment
3.2.1.2. Increase in government initiatives to monitor substance abuse
3.2.1.3. Stringent law mandating alcohol and drug testing
3.2.2. Market restraint analysis
3.2.2.1. Drug testing is considered a violation of privacy rights in some countries
3.3. Drug Of Abuse Testing Services Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Drug Of Abuse Testing Services Market: Drug Estimates & Trend Analysis
4.1. Drug Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Drug Of Abuse Testing Services Market by Drug Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Alcohol
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.2. Cannabis/Marijuana
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Cocaine
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Opioids
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Amphetamine & Methamphetamine
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. LSD
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.7. Others
4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Drug Of Abuse Testing Services Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. Global Regional Market Snapshot
5.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
5.5. North America
5.5.1. U.S.
5.5.1.1. Key country dynamics
5.5.1.2. Regulatory framework/ reimbursement structure
5.5.1.3. Competitive scenario
5.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. Canada
5.5.2.1. Key country dynamics
5.5.2.2. Regulatory framework/ reimbursement structure
5.5.2.3. Competitive scenario
5.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. Mexico
5.5.3.1. Key country dynamics
5.5.3.2. Regulatory framework/ reimbursement structure
5.5.3.3. Competitive scenario
5.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
5.6. Europe
5.6.1. UK
5.6.1.1. Key country dynamics
5.6.1.2. Regulatory framework/ reimbursement structure
5.6.1.3. Competitive scenario
5.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
5.6.2. Germany
5.6.2.1. Key country dynamics
5.6.2.2. Regulatory framework/ reimbursement structure
5.6.2.3. Competitive scenario
5.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
5.6.3. France
5.6.3.1. Key country dynamics
5.6.3.2. Regulatory framework/ reimbursement structure
5.6.3.3. Competitive scenario
5.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
5.6.4. Italy
5.6.4.1. Key country dynamics
5.6.4.2. Regulatory framework/ reimbursement structure
5.6.4.3. Competitive scenario
5.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
5.6.5. Spain
5.6.5.1. Key country dynamics
5.6.5.2. Regulatory framework/ reimbursement structure
5.6.5.3. Competitive scenario
5.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
5.6.6. Norway
5.6.6.1. Key country dynamics
5.6.6.2. Regulatory framework/ reimbursement structure
5.6.6.3. Competitive scenario
5.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
5.6.7. Sweden
5.6.7.1. Key country dynamics
5.6.7.2. Regulatory framework/ reimbursement structure
5.6.7.3. Competitive scenario
5.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
5.6.8. Denmark
5.6.8.1. Key country dynamics
5.6.8.2. Regulatory framework/ reimbursement structure
5.6.8.3. Competitive scenario
5.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Asia Pacific
5.7.1. Japan
5.7.1.1. Key country dynamics
5.7.1.2. Regulatory framework/ reimbursement structure
5.7.1.3. Competitive scenario
5.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
5.7.2. China
5.7.2.1. Key country dynamics
5.7.2.2. Regulatory framework/ reimbursement structure
5.7.2.3. Competitive scenario
5.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
5.7.3. India
5.7.3.1. Key country dynamics
5.7.3.2. Regulatory framework/ reimbursement structure
5.7.3.3. Competitive scenario
5.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
5.7.4. Australia
5.7.4.1. Key country dynamics
5.7.4.2. Regulatory framework/ reimbursement structure
5.7.4.3. Competitive scenario
5.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
5.7.5. South Korea
5.7.5.1. Key country dynamics
5.7.5.2. Regulatory framework/ reimbursement structure
5.7.5.3. Competitive scenario
5.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
5.7.6. Thailand
5.7.6.1. Key country dynamics
5.7.6.2. Regulatory framework/ reimbursement structure
5.7.6.3. Competitive scenario
5.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Latin America
5.8.1. Brazil
5.8.1.1. Key country dynamics
5.8.1.2. Regulatory framework/ reimbursement structure
5.8.1.3. Competitive scenario
5.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
5.8.2. Argentina
5.8.2.1. Key country dynamics
5.8.2.2. Regulatory framework/ reimbursement structure
5.8.2.3. Competitive scenario
5.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Middle East & Africa
5.9.1. South Africa
5.9.1.1. Key country dynamics
5.9.1.2. Regulatory framework/ reimbursement structure
5.9.1.3. Competitive scenario
5.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
5.9.2. Saudi Arabia
5.9.2.1. Key country dynamics
5.9.2.2. Regulatory framework/ reimbursement structure
5.9.2.3. Competitive scenario
5.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
5.9.3. UAE
5.9.3.1. Key country dynamics
5.9.3.2. Regulatory framework/ reimbursement structure
5.9.3.3. Competitive scenario
5.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
5.9.4. Kuwait
5.9.4.1. Key country dynamics
5.9.4.2. Regulatory framework/ reimbursement structure
5.9.4.3. Competitive scenario
5.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key company market share analysis, 2024
6.3.4. QUEST DIAGNOSTICS
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Abbott
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. CLINICAL REFERENCE LABORATORY (CRL), INC.
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. LABORATORY CORPORATION OF AMERICA HOLDINGS
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. CORDANT HEALTH SOLUTIONS
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. LEGACY MEDICAL SERVICES
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. DRUGSCAN
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. OMEGA LABORATORIES, INC.
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. PSYCHEMEDICS CORPORATION
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
6.3.13. MILLENNIUM HEALTH, LLC
6.3.13.1. Company overview
6.3.13.2. Financial performance
6.3.13.3. Product benchmarking
6.3.13.4. Strategic initiatives